Plaque Psoriasis

Immunology·MeSH: Psoriasis

Prevalence

3000.0 / 100K

Incidence

78.0 / 100K/yr

51 drugs in development·23 companies·34 clinical trials

Drug Pipeline by Phase

Approved(10)

Drug	Company
abrilada	PFIZER INC (PFE)
Brenzys (SB4)	Organon & Co. (OGN)
Hadlima (SB5)	Organon & Co. (OGN)
imuldosa	Acorda Therapeutics, Inc. (ACOR)
Renflexis (SB2)	Organon & Co. (OGN)
Taltz	ELI LILLY & Co (LLY)
Taltz®	ELI LILLY & Co (LLY)
Tremfya	Royalty Pharma plc (RPRX)
wezlana	AMGEN INC (AMGN)
yesintek	Bone Biologics Corp (BBLG)

Phase 3(22)

Drug	Company
adalimumab	GT Biopharma, Inc. (GTBP)
bimekizumab	GT Biopharma, Inc. (GTBP)
bimekizumab	Cue Biopharma, Inc. (CUE)
blinded envudeucitinib	ALUMIS INC. (ALMS)
Blinded ESK-001	ALUMIS INC. (ALMS)
envudeucitinib	ALUMIS INC. (ALMS)
ESK-001	ALUMIS INC. (ALMS)
ICP-488 Tablets	Crinetics Pharmaceuticals, Inc. (CRNX)
jnj-77242113	GH Research PLC (GHRS)
JNJ-77242113	ENANTA PHARMACEUTICALS INC (ENTA)
open-label envudeucitinib	ALUMIS INC. (ALMS)
Open-Label ESK-001	ALUMIS INC. (ALMS)
piclidenoson	Can-Fite BioPharma Ltd. (CANF)
secukinumab	GT Biopharma, Inc. (GTBP)
tak-279	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-279	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-279	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
ustekinumab	GT Biopharma, Inc. (GTBP)
ustekinumab	POINT Biopharma Global Inc. (PNT)
Ustekinumab	BRISTOL MYERS SQUIBB CO (BMY)
ustekinumab dose based on bsa	GH Research PLC (GHRS)
Vehicle cream	Organon & Co. (OGN)

Phase 2(8)

Drug	Company
bimekizumab	POINT Biopharma Global Inc. (PNT)
JNJ-77242113	Crinetics Pharmaceuticals, Inc. (CRNX)
orka-001 induction dose	Oruka Therapeutics, Inc. (ORKA)
orka-001 maintenance dose	Oruka Therapeutics, Inc. (ORKA)
orka-003	Oruka Therapeutics, Inc. (ORKA)
orka-021	Oruka Therapeutics, Inc. (ORKA)
tapinarof cream, 1%	Organon & Co. (OGN)
tqh3906	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)

Phase 1(4)

Drug	Company
ly4100511	ELI LILLY & Co (LLY)
orka-001	Oruka Therapeutics, Inc. (ORKA)
orka-002	Oruka Therapeutics, Inc. (ORKA)
PN-881	Protagonist Therapeutics, Inc (PTGX)

BLA Filed(1)

Drug	Company
Icotyde	Protagonist Therapeutics, Inc (PTGX)

Phase 4(6)

Drug	Company
Deucravacitinib	AbbVie Inc. (ABBV)
Deucravacitinib	BRISTOL MYERS SQUIBB CO (BMY)
Risankizumab	AbbVie Inc. (ABBV)
Tapinarof	Organon & Co. (OGN)
Triamcinolone	Clearside Biomedical, Inc. (CLSDQ)
ustekinumab	GH Research PLC (GHRS)

BioSniper tracks 51 drugs in development for Plaque Psoriasis across 23 companies.

There are 34 clinical trials targeting Plaque Psoriasis tracked by BioSniper.

The estimated prevalence of Plaque Psoriasis is approximately 3000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.